Guy A. MacGowan

Guy A. MacGowan

Auto-generated profile, based on publicly available information

Guy A. MacGowan

Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DSDiyar Saeed
Diyar Saeed
DFDavid Feldman
David Feldman
ABAly El Banayosy
Aly El Banayosy
EBEmma Birks
Emma Birks
EBElizabeth Blume
Elizabeth Blume
DDDavid D'ALessandro
David D'ALessandro

13 March 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
SMSimon Messer
Simon Messer
SRSally Rushton
Sally Rushton
LSLewis Simmonds
Lewis Simmonds
DMDebbie Macklam
Debbie Macklam
MHMubbasher Husain
Mubbasher Husain
MBMarius Berman
Marius Berman
The United Kingdom (UK) was one of the first countries to pioneer heart transplantation from donation after circulatory death (DCD) donors. To facilitate equity of access to DCD hearts by all UK heart transplant centers and expand the retrieval zone nationwide, a Joint Innovation Fund (JIF) pilot was provided by NHS Blood and Transplant (NHSBT) and NHS England (NHSE). The activity and outcomes of this national DCD heart pilot program are reported. This is a national multi-center, retrospective cohort study examining early outcomes of DCD heart transplants performed across 7 heart transplant centers, adult and pediatric, throughout the UK. Hearts were retrieved using the direct procurement and perfusion (DPP) technique by 3 specialist retrieval teams trained in ex-situ normothermic machine perfusion. Outcomes were compared against DCD heart transplants before the national pilot era and against contemporaneous donation after brain death (DBD) heart transplants, and analyzed using Kaplan-Meier analysis, chi-square test, and Wilcoxon's rank-sum. From September 7, 2020 to February 28, 2022, 215 potential DCD hearts were offered of which 98 (46%) were accepted and attended. There were 77 potential donors (36%) which proceeded to death within 2 hours, with 57 (27%) donor hearts successfully retrieved and perfused ex situ and 50 (23%) DCD hearts going on to be transplanted. During this same period, 179 DBD hearts were transplanted. Overall, there was no difference in the 30-day survival rate between DCD and DBD (94% vs 93%) or 90 day survival (90% vs 90%) respectively. There was a higher rate of ECMO use post-DCD heart transplants compared to DBD (40% vs 16%, p = 0.0006), and DCD hearts in the pre pilot era, (17%, p = 0.002). There was no difference in length of ICU stay (9 DCD vs 8 days DBD, p = 0.13) nor hospital stay (28 DCD vs 27 DBD days, p = 0.46). During this pilot study, 3 specialist retrieval teams were able to retrieve DCD hearts nationally for all 7 UK heart transplant centers. DCD donors increased overall heart transplantation in the UK by 28% with equivalent early posttransplant survival compared with DBD donors.

1 December 2014 in Best Practice & Research Clinical Anaesthesiology
Verified
Journal Article
Open access
Djordje G. JakovljevićDjordje G. Jakovljević
Djordje G. Jakovljević
MTMichael I. Trenell
Michael I. Trenell
GMGuy A. MacGowan
Guy A. MacGowan
Noninvasive continuous cardiac output monitoring may have wide clinical applications in anaesthesiology, emergency care and cardiology. It can improve outcomes, establish diagnosis, guide therapy and help risk stratification. The present article describes the theory behind the two noninvasive continuous monitoring methods for cardiac output assessment such as bioimpedance and bioreactance. The review discusses the advantages and disadvantages of these methods and highlights the recent method comparison studies. The use of bioimpedance and bioreactance to estimate cardiac output under haemodynamic challenges is also discussed. In particular, the article focuses on performance of the two methods in the assessment of fluid responsiveness using passive leg raising test and cardiac output response to exercise stress testing.

22 April 2009 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
RBRalf Bauer
Ralf Bauer
VSVolker Straub
Volker Straub
ABAlison Blain
Alison Blain
KBKate Bushby
Kate Bushby
GMGuy A. MacGowan
Guy A. MacGowan
Aims Duchenne muscular dystrophy (DMD) is associated with progressive cardiomyopathy. Oral corticosteroids are the gold standard for the treatment of skeletal muscle weakness; however, the effects of steroids on cardiac function have not been prospectively studied. In addition, the early role of ACE‐inhibitors (ACE‐I) is controversial. We aimed to determine the effects of steroids and ACE‐I on development of left ventricular dysfunction in the mdx mouse, a model for dystrophin‐deficient cardiomyopathy. Methods and results Orally administered captopril or prednisolone was given for 8 weeks to 16‐week‐old, male mdx mice. In vivo pressure–volume loops, fibrosis, in vivo myocyte sarcolemmal injury, and cytokine expression were assessed in treated and untreated mdx mice and age‐matched controls. Untreated mdx mice showed compensated cardiomyopathy with reduced myocardial contractility, patchy myocardial fibrosis but preserved stroke volume. Captopril treatment resulted in indirect myocardial effects of reduced afterload and direct effects of increased contractility. Prednisolone caused acute sarcolemmal injury, increased expression of myocardial TNF alpha and fibrosis, resulting in left ventricular dilatation and diastolic dysfunction. Conclusion In a mouse model of dystrophin‐deficient cardiomyopathy, ACE‐I produced haemodynamic benefit, whereas steroids accelerated progression of cardiomyopathy. Although mouse models may not entirely replicate the human condition, comprehensive monitoring of cardiac function with these therapies is essential.

19 February 2016 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
JPJehill D. Parikh
Jehill D. Parikh
KHKieren G Hollingsworth
Kieren G Hollingsworth
VKVijay Kunadian
Vijay Kunadian
ABAndrew Blamire
Andrew Blamire
GMGuy A. MacGowan
Guy A. MacGowan
Pulse wave velocity is an important measure of cardiovascular risk, and can be measured by several different techniques. We compared age-related changes in pulse wave velocity derived from carotid and femoral artery waveforms using the Vicorder device and descending thoracic aorta time velocity curves using phase contrast magnetic resonance imaging (MRI) in a group of normal healthy volunteers, without cardiovascular disease, aged between 20 and 79 years. Eighty subjects underwent same-day measurements of Vicorder and MRI pulse wave velocity measurements. Both Vicorder and MRI-based pulse wave velocity measurements were significantly increased with age (R = 0.59 and 0.57 respectively, both P < 0.0001). Vicorder and MRI pulse wave velocities were also significantly related to each other (R = 0.27, P < 0.05), and Bland Altman plots showed that on average Vicorder measurements were 1.6 m/s greater than MRI. In 5 % of cases, agreement between the values of the two techniques were above and below 2 standard deviations, and these were at higher levels of pulse wave velocities. Multiple linear stepwise regression analysis confirmed highly significant relationships of both techniques to age (both P < 0.0001), and MRI was also significantly related to heart rate (P = 0.006) but Vicorder was not. Both Vicorder and MRI perform similarly in detecting age-related changes in pulse wave velocity. Thus, the choice of using one or the other will depend on other aspects of the investigation, such as the need for portability favouring Vicorder, or need for additional cardiovascular imaging favouring MRI. ClinicalTrials.Gov identifier NCT01504828

21 September 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
NONduka C Okwose
Nduka C Okwose
NONicola O'BRien
Nicola O'BRien
SCSarah Charman
Sarah Charman
SCSophie Cassidy
Sophie Cassidy
DBDavid Brodie
David Brodie
LALeah Avery
Leah Avery
Objectives Clinical guidelines recommend regular physical activity for patients with heart failure to improve functional capacity and symptoms and to reduce hospitalisation. Cardiac rehabilitation programmes have demonstrated success in this regard; however, uptake and adherence are suboptimal. Home-based physical activity programmes have gained popularity to address these issues, although it is acknowledged that their ability to provide personalised support will impact on their effectiveness. This study aimed to identify barriers and facilitators to engagement and adherence to a home-based physical activity programme, and to identify ways in which it could be integrated into the care pathway for patients with heart failure. Design A qualitative focus group study was conducted. Data were analysed using thematic analysis. Participants A purposive sample of 16 patients, 82% male, aged 68±7 years, with heart failure duration of 10±9 years were recruited. Intervention A 12-week behavioural intervention targeting physical activity was delivered once per week by telephone. Results Ten main themes were generated that provided a comprehensive overview of the active ingredients of the intervention in terms of engagement and adherence. Fear of undertaking physical activity was reported to be a significant barrier to engagement. Influences of family members were both barriers and facilitators to engagement and adherence. Facilitators included endorsement of the intervention by clinicians knowledgeable about physical activity in the context of heart failure; ongoing support and personalised feedback from team members, including tailoring to meet individual needs, overcome barriers and increase confidence. Conclusions Endorsement of interventions by clinicians to reduce patients’ fear of undertaking physical activity and individual tailoring to overcome barriers are necessary for long-term adherence. Encouraging family members to attend consultations to address misconceptions and fear about the contraindications of physical activity in the context of heart failure should be considered for adherence, and peer-support for long-term maintenance. Trial registration number NCT03677271.